ARO-APOC3 PFS
AROAPOC3-3006
Phase 3 small_molecule active
Quick answer
ARO-APOC3 PFS for Hypertriglyceridemia (HTG) is a Phase 3 program (small_molecule) at Arrowhead Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arrowhead Pharmaceuticals Ireland Limited
- Indication
- Hypertriglyceridemia (HTG)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active